inspec Inc.
Supplementary Explanation Material for Fundraising via the 19th Series Stock Acquisition Rights (with Exercise Price Adjustment Provisions)
Executing fundraising of approximately JPY 2.0 billion through stock acquisition rights (with exercise price adjustment provisions), targeting working capital of JPY 1.5 billion and R&D funds of JPY 0.5 billion. Dilution could be as high as 58.8% (voting rights basis 37.0%), but controllable through exercise delay and acquisition provisions. Plans to allocate funds to working capital and R&D over the next two and a half years.
Key Figures
- Intended fundraising amount: JPY 2.0 billion (working capital JPY 1.5 billion, R&D JPY 0.5 billion)
- Dilution: Up to 58.8% (voting rights base 37.0%)
- Working capital expenditure period: 2026 September–2028 April
- R&D expenditure period: 2026 September–2028 April
AI要約
Overview
This supplementary material explains the positioning of fundraising via the 19th series stock acquisition rights (with exercise price adjustment provisions) and the use of funds, assuming a fundraising amount of JPY 2.0 billion to be allocated to working capital of JPY 1.5 billion and R&D funding of JPY 0.5 billion. It aims to balance increased order intake-driven working capital needs with development investments for next-generation products, strengthening the financial base and enhancing corporate value.
Impact on investors and outlook
Dilution could reach up to approximately 59% (based on voting rights), but the process can be controlled via exercise pause provisions and acquisition terms. Funds will be deployed toward growth investments to target medium- to long-term sales and earnings expansion. Anticipated allottees include overseas institutional investors, with planned secondary market disposals generally requiring company approval and intended to be handled off-market.
Inspec Co., Ltd.
Company overview · Stock price · Financial data · All IR
